Wheeler Bio announced a new strategic agreement with Charles River to offer Wheeler Bio’s Portable CMC platform to Charles River Laboratory clients. The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRL:
- Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
- Charles River announces stem cells collaboration with Pluristyx
- Charles River price target raised to $235 from $205 at Morgan Stanley
- Charles River downgraded to Neutral at Guggenheim on valuation
- Charles River price target raised to $260 from $193 at TD Cowen
